Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Clinical evidence

ARCHER

85 evidence topics · 31 sources

Objective
Location and study date
Registered study dates
MilestoneRegistry record
Study start (actual)“2021-02-26”
Primary completion (actual)“2023-03-28”
Study completion (actual)“2023-09-13”
Study site countries
Study design
Registered design elements
Design elementRegistry record
Phase“Phase 2”
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Registered arms and interventions
Study outcomes
Rationale for using rate of change in geographic atrophy lesion area by fundus autofluorescence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by population and arm
PopulationANX007 EMANX007 EOMSham
Baseline (ITT)“89”“92”“89”
Primary endpoint (non-subfoveal at baseline)“38”“43”“45”
LLVA and LLVD ≥15-letter loss events“79”“85”“79”
Safety“89”“92”“89”
PopulationANX007 pooled
Primary endpoint (non-subfoveal at baseline)“81”
Description of analysis sets
Results
Participant disposition
Registry participant flow through the overall study
Milestone or reasonANX007 EMANX007 EOMSham
Started“89”“92”“89”
Received at least 1 dose of study drug“89”“92”“89”
Completed“73”“77”“76”
Not completed“16”“15”“13”
Adverse event“4”“7”“3”
Death“0”“0”“1”
Lost to follow-up“2”“2”“1”
Other than specified“1”“0”“1”
Physician decision“1”“0”“1”
Protocol violation“1”“1”“0”
Withdrawal by subject“7”“5”“6”
Treatment discontinuation by arm
MeasureSham pooledANX007 EMANX007 EOM
Discontinued treatment“10 (11.2%)”“13 (14.6%)”“11 (12.0%)”
Baseline characteristics
Registry baseline characteristics, ITT population
CharacteristicANX007 EMANX007 EOMShamTotal
Participants“89”“92”“89”“270”
Age, years, mean (SD)“79.7(8.64)”“80.5(8.53)”“79.8(7.49)”“80.0(8.22)”
Female, participants“47”“60”“59”“166”
Male, participants“42”“32”“30”“104”
Hispanic or Latino, participants“1”“2”“3”“6”
White, participants“87”“89”“87”“263”
Asian, participants“1”“2”“2”“5”
Study eye GA lesion size, mm², mean (SD)“7.2789(3.96342)”“7.5284(4.09946)”“7.2802(3.98783)”“7.3643(4.00505)”
BCVA, ETDRS letters, mean (SD)“58.8(17.19)”“57.9(15.30)”“58.5(16.23)”“58.4(16.19)”
LLVA, ETDRS letters, mean (SD)“35.3(16.41)”“29.6(15.72)”“34.2(18.05)”“33.0(16.86)”
LLVA and LLVD, participants analyzed“87 participants”“91 participants”“85 participants”“263 participants”
LLVD, ETDRS letters, mean (SD)“23.5(16.08)”“28.3(18.39)”“25.0(15.70)”“25.7(16.86)”
Lesion location, lesion size category, fellow-eye CNV, and multifocality
CharacteristicSham pooled (N=89)Vonaprument EM (N=89)Vonaprument EOM (N=92)
Foveal lesion“49.4%”“57.3%”“53.3%”
GA lesion < 7.5 mm²“61.8%”“58.4%”“57.6%”
Fellow eye CNV“22.5%”“24.7%”“17.4%”
Multifocality, n (%)“65 (73.0%)”“61 (68.5%)”“67 (72.8%)”
Efficacy results
Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome
MeasureANX007 EMANX007 EOMSham
Participants analyzed“89”“92”“89”
Number of events with confirmed ≥15-letter loss“4”“8”“15”
Confirmed BCVA ≥15-letter loss: final data under two event definitions
Event definition and measureShamVonaprument EMVonaprument EOM
Through month 12 or last visit: participants with loss“19/89”“5/89”“9/92”
Through month 12 or last visit: percentage“21.3%”“5.6%”“9.8%”
Through month 12 or last visit: nominal p-value vs pooled sham“---”“0.0021”“0.032”
Month 12 event confirmed at month 15: participants with loss“15/89”“4/89”“8/92”
Month 12 event confirmed at month 15: percentage“16.9%”“4.5%”“8.7%”
Month 12 event confirmed at month 15: nominal p-value vs pooled sham“---”“0.0076”“0.0994”
Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis
Threshold and measureShamEMEOM
≥10-letter loss: participants with loss“23/89”“14/89”“19/92”
≥10-letter loss: percentage“25.8%”“15.7%”“20.7%”
≥10-letter loss: nominal p-value vs sham“---”“0.096”“0.408”
≥20-letter loss: participants with loss“15/89”“4/89”“6/92”
≥20-letter loss: percentage“16.9%”“4.5%”“6.5%”
≥20-letter loss: nominal p-value vs sham“---”“0.008”“0.030”
Low-luminance visual acuity: registry results
MeasureANX007 EMANX007 EOMSham
Change from baseline to month 12, least squares mean (SE), letters“-1.4(1.29)”“-2.8(1.25)”“-4.8(1.31)”
Participants analyzed for ≥15-letter loss“79”“85”“79”
Number of events with ≥15-letter LLVA loss“6”“8”“16”
Low-luminance visual acuity and deficit: final data
MeasureShamEMEOM
LLVA ≥15-letter loss: participants with loss“16/79”“6/79”“8/85”
LLVA ≥15-letter loss: percentage“20.3%”“7.6%”“9.4%”
LLVA ≥15-letter loss: nominal p-value vs sham“--”“0.0216”“0.0497”
LLVD ≥15-letter worsening: participants with worsening“13/79”“4/79”“8/85”
LLVD ≥15-letter worsening: percentage“16.5%”“5.1%”“9.4%”
LLVD ≥15-letter worsening: nominal p-value vs sham“--”“0.0209”“0.1774”
Mean change in LLVA at month 12“-4.8”“-1.4”“-2.8”
Mean change in LLVA at month 12: nominal p-value vs sham“---”“0.0592”“0.2664”
Low-luminance visual deficit: registry results
MeasureANX007 EMANX007 EOMSham
Change from baseline to month 12, least squares mean (SE), letters“-0.4(1.55)”“1.3(1.50)”“0.6(1.57)”
Participants analyzed for ≥15-letter worsening“79”“85”“79”
Number of events with ≥15-letter LLVD worsening“4”“8”“13”
Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA
Post hoc analysis: participants with subfoveal lesions at baseline
Measure, subfoveal populationShamVonaprument EMVonaprument EOM
Confirmed BCVA ≥15-letter loss: participants with loss“10/44”“3/51”“7/49”
Confirmed BCVA ≥15-letter loss: percentage“22.7%”“5.9%”“14.3%”
Confirmed BCVA ≥15-letter loss: nominal p-value vs sham“---”“.0172”“.2930”
LLVA ≥15-letter loss: participants with loss“7/41”“2/50”“1/48”
LLVA ≥15-letter loss: percentage“17.1%”“4.0%”“2.1%”
LLVA ≥15-letter loss: nominal p-value vs sham“---”“.0137”“.0377”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Deaths, serious adverse events, and other adverse events, registry results
MeasureANX007 EMANX007 EOMSham
All-cause mortality“2/89 (2.25%)”“3/92 (3.26%)”“2/89 (2.25%)”
Participants with serious adverse events“21/89 (23.60%)”“16/92 (17.39%)”“16/89 (17.98%)”
Participants with other (non-serious) adverse events“21/89 (23.60%)”“20/92 (21.74%)”“23/89 (25.84%)”
Ocular serious adverse events, registry results
Non-ocular serious adverse events in two or more participants in any group, registry results
Non-serious adverse events at a frequency of 5% or more, registry results
Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy
Adverse event, n (%)Sham (N=89)Vonaprument EM (N=89)Vonaprument EOM (N=92)
Choroidal neovascularization“3 (3.4%)”“4 (4.5%)”“4 (4.3%)”
Endophthalmitis“0”“1 (1.1%)”“2 (2.2%)”
Retinal vascular occlusion“0”“0”“1^ (1.1%)”
Retinal vasculitis“0”“0”“0”
Intraocular inflammation“0”“2 (2.2%)”“1 (1.1%)”
Ischemic optic neuropathy“0”“0”“0”
Study limitations
Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results
  • Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
  • Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
  • Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
  • Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
  • No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
  • Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.